Rock Springs Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Rock Springs Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-727,673	Closed	-$4.51M	–	112
2024 Q2	$4.51M	Hold	727,673	–	–	0.14%	85
2024 Q1	$6.87M	Hold	727,673	–	–	0.17%	86
2023 Q4	$4.91M	Hold	727,673	–	–	0.12%	82
2023 Q3	$3.23M	Hold	727,673	–	–	0.09%	90
2023 Q2	$2.4M	Hold	727,673	–	–	0.06%	104
2023 Q1	$2.07M	Buy	727,673 +343,083	+89%	+$3.07M	0.05%	104
2022 Q4	$2.8M	Hold	384,590	–	–	0.07%	100
2022 Q3	$3.11M	Hold	384,590	–	–	0.08%	104
2022 Q2	$1.88M	Sell	384,590 -50,000	-12%	-$489K	0.05%	115
2022 Q1	$10.3M	Sell	434,590 -22,400	-5%	-$317K	0.26%	80
2021 Q4	$8.08M	Buy	456,990 +1,700	+0.4%	+$33.7K	0.19%	100
2021 Q3	$12.8M	Buy	+455,290	New	+$8.63M	0.27%	94

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rock Springs Capital Management's FULC Position: Q3 2024 in Review

Rock Springs Capital Management sold out of Fulcrum Therapeutics (FULC) in Q3 2024, closing a stake of 727,673 shares — an estimated $4.51M sold.

Rock Springs Capital Management first reported a position in FULC in Q3 2021 and held it in 12 quarters. The position peaked at $12.8M in Q3 2021. 130 funds tracked by Wall St. Rank hold FULC as of Q3 2024.

Rock Springs Capital Management reported no remaining Fulcrum Therapeutics position as of Q3 2024 after selling out during the quarter.
Rock Springs Capital Management sold 727,673 Fulcrum Therapeutics shares in Q3 2024, an estimated $4.51M.
Rock Springs Capital Management first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 12 quarters.
Rock Springs Capital Management's Fulcrum Therapeutics position peaked at $12.8M in Q3 2021.
130 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2024.

Based on Rock Springs Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.